HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children
HCA Healthcare announced the publication of a New England Journal of Medicine study led by Dr. Haydar Frangoul evaluating the use of CRISPR-based therapy exa-cel in children ages 5-11 with sickle cell disease and beta thalassemia. The study found that all evaluated patients with beta thalassemia achieved transfusion independence for at least 12 months, while all evaluated sickle cell patients remained free of severe vaso-occlusive crises for the same period.
Key figures
- Hospitals
- 189
- Ambulatory sites
- 2600
- Study enrollment
- 26
- Annual transplants
- 1600
- Crisis free patients
- 8
- Sickle cell patients
- 11
- Annual patient encounters
- 47000000
- Beta thalassemia patients
- 15
- Transfusion independence patients
- 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.